PHENTrials.com

PHENTrials.com provides easy access to clinical trials for all prostate cancer diagnoses. Patients can identify and review trials that may be appropriate for them.

 

“Increasing Participation in Prostate Cancer Clinical Trials to Save Lives.”

PHENTrials.com

PHENTrials.com provides easy access to clinical trials for all prostate cancer diagnoses. Patients can identify and review trials that may be appropriate for them.

Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

Search
Prostate Health

Find Your Trial

PHEN’s Find Your Trial (FYT) search tool connects patients with prostate cancer clinical trials based on a patient’s diagnosis and where they are located.

Prostate Cancer Diagnoses

Low Risk

Patients with an initial diagnosis of PSA less than 10, Gleason 6/Grade Group 1. Cancer involves one half of one side of the prostate or less.

Intermediate Risk

(Favorable): Patients with an initial diagnosis that includes one of the following: Gleason 7/Grade Group 2, PSA 10-20, or cancer involves more than one-half of one side of the prostate or involves both sides of the prostate

(Unfavorable): Patients with an initial diagnosis of Gleason 7/Grade Group 3 or that includes 2 or 3 of the following: Gleason 7/Grade Group 2, PSA 10-20, cancer involves more than one-half of one side of the prostate or involves both sides of the prostate.

High Risk

Patients with an initial diagnosis that includes one of the following: PSA more than 20, Gleason 8-9/Grade Group 4-5, tumor has spread a little outside the prostate.

Cancer Recurrence

For patients with a PSA biochemical recurrence after prostate removal through surgery or after radiation.

Non-Metastatic Castration Resistant

NMCRPC is castration-resistant prostate cancer without signs of distant metastases.

Metastatic Castration Sensitive

For patients with metastatic prostate cancer that still responds to hormone (androgen deprivation) treatment.

Metastatic Castration Resistant

MCRPC is castration-resistant prostate cancer with distant metastases.

Neuroendocrine

Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer that may arise in new patients or those previously treated with hormonal therapies for prostate adenocarcinoma as a mechanism of resistance.

Patient Summaries

Prostate Health

MEVPRO-2

The primary objective of this clinical trial is to assess the efficacy of combining the study medicine (mevrometostat) with a standard therapy (enzalutamide) to treat metastatic castration–resistant prostate cancer (mCRPC) compared to placebo in combination with enzalutamide.

VISIT

AMG509

This clinical trial is for patients who have metastatic castration resistant prostate cancer (mCRPC) and failed to respond to abiraterone acetate or enzalutamide (but not both) and to taxane-based chemotherapy.

VISIT
Prostate Health

Libertas

The LIBERTAS STUDY is researching a way to potentially treat a type of prostate cancer that still responds to hormone therapy. Prostate cancer that spreads to other parts of the body but can still be controlled by interfering with the hormone function of the cancer is called metastatic castration-sensitive prostate cancer (mCSPC).

VISIT
Prostate Health

Omaha-003

The Omaha-003 clinical trial is for participants who have metastatic castration-resistant prostate cancer that failed to respond to drugs or surgery to block the testes from making hormones and after treatment with other drugs for prostate cancer. 

VISIT
Prostate Health

MEVPRO-1

The primary objective of this clinical trial is to assess the efficacy of combining the study medicine (mevrometostat) with a standard therapy (enzalutamide) to treat metastatic castration-resistant prostate cancer (mCRPC), which will be compared to standard treatments alone (either enzalutamide or docetaxel).

VISIT
Prostate Health

Lorikeet

Lorigerlimab is an investigational drug being tested in clinical trials. It is designed to block two checkpoints, telling the immune system cells to wake up and start killing cancer cells. Checkpoint inhibitors, including lorigerlimab, may cause side effects.

VISIT
Prostate Health

Omaha-004

The Omaha-004 clinical trial is for participants who have metastatic castration-resistant prostate cancer that failed to respond to drugs or surgery to block the testes from making hormones and after treatment with other drugs for prostate cancer. 

VISIT
Prostate Health

MK-5684-01A Substudy for Advanced Prostate Cancer

VISIT

Our Partners

Prostate Health
Prostate Health
Prostate Health
Prostate Health
Prostate Health
Prostate Health

For Partnership Interest

Let's Connect

This information is for educational purposes only and not intended as medical advice.
Patients should consult their medical doctor for advice and recommendations about specific clinical trials.

Pin It on Pinterest